Areas of Expertise
  • Mergers and Acquisitions
  • Financings
  • Corporate Governance
  • Life Sciences
  • Medical Devices
  • Pharma
  • Diagnostics
Contact Mark Murray
Download vCard
Recent Blog Posts
Life Sciences Companies: Sell Now or Sell Later?
Read More


All Posts

Mark Murray

Mark Murray joined FLG in 2014.  Mark brings over 25 years  of experience in corporate finance in both public and private companies in the life science sector.

Mark helps companies by providing both corporate and financial strategic planning and execution, early to late stage financings, M&A, licensing, OEM and coaching to senior management teams.  His functional experience includes finance, business development, IT, HR, facilities as well as a key member of senior management teams and working with Boards of Directors.

Prior to FLG, Mark was Chief Financial Officer of OptiMedica Corporation, a ventured back company in ophthalmology, which was successfully acquired by Abbott Labs in 2013.  During his time at OptiMedica, Mark oversaw equity/debt financing greater than $90 million, sold part of the business (asset sale) in 2010 for $60 million and grew revenue for OptiMedica’s laser cataract business to nearly $20 million prior to the acquisition of OptiMedica by Abbott Labs for $400 million.

Previously to OptiMedica, Mark was Chief Financial Officer of Emphasys Medical, a ventured back interventional pulmonology company, in which he filed the company’s S-1 initial public offering and raised $15 in debt financing.

Previously, Mark spent 21 years with Guidant Corporation, including its predecessor Advanced Cardiovascular System and its successor Abbott Labs/Boston Scientific. Mark was part of Guidant’s senior management team and participated in its $1 billion IPO thru its exit in 2006 for $27 billion (Abbott Labs/Boston Scientific).  During those 21 years, Mark led the finance team of Guidant’s Vascular Intervention group overseeing revenue growth from less than $20 million to over $1.3 billion; leading the business development team in strategic transactions that included M&A, drug in-licensing, OEM and equity investments; and overseeing the global installation of SAP.

Mark started his career with international CPA firms of Ernst & Whinney and Main Hurdman.

Mark holds a BS in business administration (accounting) from San Francisco State University.



Mark's Perspective on FLG

FLG has allowed me to have far greater experience and impact on my life science clients.  For example, in one year I participated in the raise of $1 billion for one client, participated in another client being successfully acquired and provided coaching to a CFO whose company went public.   That type of experience is invaluable to our clients.

- Mark Murray


Sector Experience
  • Biopharma
  • Diagnostics
  • Life Sciences
  • Medtech
Selected Engagements
Oyster Point Pharma, Inc. Biopharma Private
ClarVista Medical Medtech Interim CFO Private
GRAIL, Inc. Biopharma Interim CFO Private
Benevenue Medical Medtech Permanent CFO
BAROnova, Inc. Medtech Permanent CFO Private
Oculeve, Inc. Medtech
Auxogyn, Inc. Diagnostics Interim CFO Private